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Résumé en
anglais
The purpose of this study was to identify the incidence, causes and impact of non-
adherence to oral and subcutaneous chronic treatments for patients with
polycythemia vera or essential thrombocythemia. Patients receiving cytoreductive
drugs for polycythemia vera or essential thrombocythemia were recruited at our
institution ( registry). They completed a one-shot questionnaire designed by
investigators ( study). Data about complications (thrombosis, transformation and
death) at any time in the patient's life (before diagnosis, up until consultation and
after the completion of the questionnaire) were collected. Sixty-five (22.7%) of 286
patients reported poor adherence (<90%) to their treatment with cytoreductive
drugs and 46/255/18%) also declared non-adherence to antithrombotic drugs. In
total, 85/286 patients (29.7%) declared they did not adhere to their treatment.
Missing an intake was rare and was mostly due to forgetfulness especially during
occupational travel and holidays. Patients who did not adhere to their treatment
were characterized by younger age, living alone, having few medications but a high
numbers of pills and determining their own schedule of drug intake. Having
experienced thrombosis or hematologic evolution did not influence the adherence
rate. Non-adherence to oral therapy was associated with a higher risk of phenotypic
evolution (7.3 1.8%, =0.05). For patients treated for polycythemia vera or essential
thrombocythemia, non-adherence to cytoreductive and/or antithrombotic therapies is
frequent and is influenced by age, habitus and concomitant treatments, but not by
disease history or treatment side effects. Phenotypic evolution seems to be more
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